Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $6.00.

Separately, Citigroup assumed coverage on Mersana Therapeutics in a research note on Friday, November 15th. They issued a “buy” rating and a $5.00 target price on the stock.

Mersana Therapeutics Price Performance

NASDAQ MRSN opened at $1.43 on Friday. The company has a market cap of $176.65 million, a PE ratio of -2.34 and a beta of 1.40. Mersana Therapeutics has a 52-week low of $1.22 and a 52-week high of $6.28. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. The firm’s 50 day moving average price is $2.06 and its 200-day moving average price is $1.92.

Mersana Therapeutics (NASDAQ:MRSN) last announced its earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. The business had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $7.53 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The business’s revenue for the quarter was up 63.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.35) EPS. Sell-side analysts forecast that Mersana Therapeutics will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Mersana Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE purchased a new position in Mersana Therapeutics in the 3rd quarter worth $31,000. Dynamic Technology Lab Private Ltd acquired a new position in Mersana Therapeutics in the 3rd quarter worth approximately $34,000. Intech Investment Management LLC purchased a new position in Mersana Therapeutics during the 3rd quarter worth approximately $52,000. Quarry LP purchased a new position in Mersana Therapeutics during the 3rd quarter worth approximately $57,000. Finally, Algert Global LLC acquired a new stake in Mersana Therapeutics during the 2nd quarter valued at approximately $90,000. Institutional investors and hedge funds own 93.92% of the company’s stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.